184 related articles for article (PubMed ID: 26752545)
1. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Xu J; Sun HH; Fletcher CD; Hornick JL; Morgan EA; Freeman GJ; Hodi FS; Pinkus GS; Rodig SJ
Am J Surg Pathol; 2016 Apr; 40(4):443-53. PubMed ID: 26752545
[TBL] [Abstract][Full Text] [Related]
2. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
4. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
8. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in small cell neuroendocrine carcinomas.
Schultheis AM; Scheel AH; Ozretić L; George J; Thomas RK; Hagemann T; Zander T; Wolf J; Buettner R
Eur J Cancer; 2015 Feb; 51(3):421-6. PubMed ID: 25582496
[TBL] [Abstract][Full Text] [Related]
10. Histiocytic and dendritic cell neoplasms: Reappraisal of a Japanese series based on t(14;18) and neoplastic PD-L1 expression.
Okada K; Takahara T; Suzuki Y; Kohno K; Sakakibara A; Satou A; Takahashi E; Nakamura S
Pathol Int; 2021 Jan; 71(1):24-32. PubMed ID: 33238073
[TBL] [Abstract][Full Text] [Related]
11. The histiocytoses: clinical presentation and differential diagnosis.
Gonzalez CL; Jaffe ES
Oncology (Williston Park); 1990 Nov; 4(11):47-60; discussion 60, 62. PubMed ID: 2150325
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of programmed death ligands in naturally occurring postweaning multisystemic wasting syndrome.
Yue F; Cheng A; Zhu Y; Li P; Zhang Y; Sun G; Wang M; Wang X
Viral Immunol; 2015 Mar; 28(2):101-6. PubMed ID: 25594677
[TBL] [Abstract][Full Text] [Related]
16. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
17. High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms.
Huang W; Qiu T; Zeng L; Zheng B; Ying J; Feng X
Oncotarget; 2016 Nov; 7(48):78355-78362. PubMed ID: 27823979
[TBL] [Abstract][Full Text] [Related]
18. Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells.
Martínez VG; Hidalgo L; Valencia J; Hernández-López C; Entrena A; del Amo BG; Zapata AG; Vicente A; Sacedón R; Varas A
Eur J Immunol; 2014 Apr; 44(4):1031-8. PubMed ID: 24532425
[TBL] [Abstract][Full Text] [Related]
19. Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.
Roeven MW; Hobo W; van der Voort R; Fredrix H; Norde WJ; Teijgeler K; Ruiters MH; Schaap N; Dolstra H
J Immunother; 2015 May; 38(4):145-54. PubMed ID: 25839440
[TBL] [Abstract][Full Text] [Related]
20. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
